Drug Trial Radar · NCT04486313
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Last checked: Nov 20, 2026Latest source record: Mar 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
935
Actual
Start
Aug 13, 2020
Primary completion
Feb 8, 2021
Study completion Feb 8, 2021
Sponsor
- Lead sponsor
- Romark Laboratories L.C.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Conditions
- COVID-19
Interventions
NitazoxanideDrug
Two nitazoxanide 300 mg tablets administered orally twice daily with food for 5 days
PlaceboDrug
Two placebo tablets administered orally twice daily with food for 5 days
Vitamin Super B-ComplexDietary supplement
Vitamin Super B-Complex administered orally twice daily to maintain the blind
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Sustained Clinical RecoveryTime frame: Up to 21 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Invesclinic US LLC
Fort Lauderdale, Florida
RH Medical Urgent Care
The Bronx, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.